Mirae Asset Global Investments Co. Ltd. Trims Holdings in GoodRx Holdings, Inc. (NASDAQ:GDRX)

Mirae Asset Global Investments Co. Ltd. reduced its holdings in shares of GoodRx Holdings, Inc. (NASDAQ:GDRX) by 22.3% in the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 112,677 shares of the company’s stock after selling 32,293 shares during the period. Mirae Asset Global Investments Co. Ltd.’s holdings in GoodRx were worth $755,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently made changes to their positions in GDRX. Barclays PLC boosted its stake in shares of GoodRx by 219.8% during the 2nd quarter. Barclays PLC now owns 18,509 shares of the company’s stock valued at $102,000 after buying an additional 12,722 shares during the last quarter. Harbor Capital Advisors Inc. lifted its stake in GoodRx by 22.7% during the third quarter. Harbor Capital Advisors Inc. now owns 14,995 shares of the company’s stock worth $84,000 after purchasing an additional 2,771 shares during the last quarter. Bank of New York Mellon Corp lifted its stake in GoodRx by 7.5% during the third quarter. Bank of New York Mellon Corp now owns 189,560 shares of the company’s stock worth $1,067,000 after purchasing an additional 13,235 shares during the last quarter. Mackenzie Financial Corp bought a new position in GoodRx during the third quarter worth $68,000. Finally, Olympiad Research LP lifted its stake in GoodRx by 56.0% during the third quarter. Olympiad Research LP now owns 50,184 shares of the company’s stock worth $283,000 after purchasing an additional 18,009 shares during the last quarter. 63.77% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several brokerages recently issued reports on GDRX. KeyCorp upgraded GoodRx from a “sector weight” rating to an “overweight” rating and set a $9.00 price objective on the stock in a research note on Wednesday, April 10th. SVB Leerink began coverage on GoodRx in a research note on Monday, February 26th. They set an “outperform” rating and a $8.00 price objective on the stock. Leerink Partnrs restated an “outperform” rating on shares of GoodRx in a research note on Monday, February 26th. Truist Financial raised their target price on GoodRx from $7.50 to $8.00 and gave the company a “hold” rating in a research note on Friday, March 1st. Finally, Royal Bank of Canada raised their target price on GoodRx from $7.00 to $8.00 and gave the company a “sector perform” rating in a research note on Friday, March 1st. One equities research analyst has rated the stock with a sell rating, eight have assigned a hold rating and ten have issued a buy rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $8.78.

GoodRx Price Performance

Shares of GDRX opened at $6.96 on Thursday. The firm has a market capitalization of $2.75 billion, a price-to-earnings ratio of -347.83, a price-to-earnings-growth ratio of 3.65 and a beta of 1.42. The company has a debt-to-equity ratio of 0.85, a quick ratio of 7.12 and a current ratio of 7.12. GoodRx Holdings, Inc. has a one year low of $4.14 and a one year high of $9.37. The stock’s fifty day moving average is $6.91 and its 200-day moving average is $6.25.

GoodRx (NASDAQ:GDRX) last issued its quarterly earnings results on Thursday, February 29th. The company reported $0.02 EPS for the quarter, meeting analysts’ consensus estimates of $0.02. The company had revenue of $196.64 million for the quarter, compared to analyst estimates of $195.59 million. GoodRx had a positive return on equity of 2.45% and a negative net margin of 1.18%. Equities analysts anticipate that GoodRx Holdings, Inc. will post 0.23 EPS for the current year.

GoodRx Company Profile

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.